Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice

Cancer Cell

Volumn 7, Issue 5, 2005, Pages 469-483

  Hingorani, Sunil R ^a   Wang, Lifu ^a   Multani, Asha S ^c   Combs, Chelsea ^a   Deramaudt, Therese B ^a,b   Hruban, Ralph H ^d   Rustgi, Anil K ^a,b   Chang, Sandy ^c   Tuveson, David A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHROMOSOMAL INSTABILITY; EROSION; GENE EXPRESSION; GENE FUNCTION; GENE TRANSLOCATION; GENETICS; GENOMIC INSTABILITY; METASTASIS; MOUSE; MUTATION; NONHUMAN; ONCOGENE; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PANCREAS DUCT; PATHOGENESIS; PRIORITY JOURNAL; SUPPRESSOR GENE; TELOMERE; TRP53 GENE; ANIMAL; C57BL MOUSE; CENTROSOME; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; DISEASE COURSE; GENE EXPRESSION REGULATION; GENE REARRANGEMENT; METABOLISM; MISSENSE MUTATION; MOUSE MUTANT; MOUSE STRAIN; PANCREAS CARCINOMA; PATHOLOGY; SURVIVAL; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE;

CADHERIN; CRE RECOMBINASE; HOMEODOMAIN PROTEIN; INSULIN PROMOTER FACTOR 1; INTEGRASE; KRAS2 PROTEIN, MOUSE; ONCOPROTEIN; PROTEIN P21; PROTEIN P53; RAS PROTEIN; TRANSACTIVATOR PROTEIN;

ANIMALS; CADHERINS; CARCINOMA, PANCREATIC DUCTAL; CENTROSOME; CHROMOSOMAL INSTABILITY; CHROMOSOME ABERRATIONS; CYTOGENETIC ANALYSIS; DISEASE PROGRESSION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE REARRANGEMENT; GENES, TUMOR SUPPRESSOR; HOMEODOMAIN PROTEINS; INTEGRASES; MICE; MICE, INBRED C57BL; MICE, INBRED STRAINS; MICE, MUTANT STRAINS; MICE, TRANSGENIC; MUTATION, MISSENSE; NEOPLASM METASTASIS; ONCOGENE PROTEINS V-ERBB; PROTO-ONCOGENE PROTEINS P21(RAS); RAS PROTEINS; SURVIVAL ANALYSIS; TELOMERE; TRANS-ACTIVATORS; TRANSLOCATION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 19344362405     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2005.04.023     Document Type: Article

References (59)

1. A.J. Aguirre, N. Bardeesy, M. Sinha, L. Lopez, D.A. Tuveson, J. Horner, M.S. Redston, and R.A. DePinho Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma Genes Dev. 17 2003 3112 3126
2. D.C. Allison, S. Piantadosi, R.H. Hruban, W.C. Dooley, E.K. Fishman, C.J. Yeo, K.D. Lillemoe, H.A. Pitt, P. Lin, and J.L. Cameron DNA content and other factors associated with ten-year survival after resection of pancreatic carcinoma J. Surg. Oncol. 67 1998 151 159
3. S.E. Artandi, S. Chang, S.L. Lee, S. Alson, G.J. Gottlieb, L. Chin, and R.A. DePinho Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice Nature 406 2000 641 645
4. D.M. Berman, S.S. Karhadkar, A. Maitra, R. Montes De Oca, M.R. Gerstenblith, K. Briggs, A.R. Parker, Y. Shimada, J.R. Eshleman, D.N. Watkins, and P.A. Beachy Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours Nature 425 2003 846 851
5. J.M. Birch, R.D. Alston, R.J. McNally, D.G. Evans, A.M. Kelsey, M. Harris, O.B. Eden, and J.M. Varley Relative frequency and morphology of cancers in carriers of germline TP53 mutations Oncogene 20 2001 4621 4628
6. D.J. Brat, K.D. Lillemoe, C.J. Yeo, P.B. Warfield, and R.H. Hruban Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas Am. J. Surg. Pathol. 22 1998 163 169
7. H.A. Burris 3rd, M.J. Moore, J. Andersen, M.R. Green, M.L. Rothenberg, M.R. Modiano, M.C. Cripps, R.K. Portenoy, A.M. Storniolo, and P. Tarassoff Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial J. Clin. Oncol. 15 1997 2403 2413
8. C. Caldas, S.A. Hahn, L.T. da Costa, M.S. Redston, M. Schutte, A.B. Seymour, C.L. Weinstein, R.H. Hruban, C.J. Yeo, and S.E. Kern Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma Nat. Genet. 8 1994 27 32
9. U. Cavallaro, and G. Christofori Cell adhesion and signalling by cadherins and Ig-CAMs in cancer Nat. Rev. Cancer 4 2004 118 132
10. Y. Cho, S. Gorina, P.D. Jeffrey, and N.P. Pavletich Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations Science 265 1994 346 355
11. J.D. Day, J.A. Digiuseppe, C. Yeo, M. Lai-Goldman, S.M. Anderson, S.N. Goodman, S.E. Kern, and R.H. Hruban Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms Hum. Pathol. 27 1996 119 124
12. T. de Lange Protection of mammalian telomeres Oncogene 21 2002 532 540
13. C.J. Di Como, C. Gaiddon, and C. Prives p73 function is inhibited by tumor-derived p53 mutants in mammalian cells Mol. Cell. Biol. 19 1999 1438 1449
14. L.A. Donehower, M. Harvey, B.L. Slagle, M.J. McArthur, C.A. Montgomery Jr., J.S. Butel, and A. Bradley Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours Nature 356 1992 215 221
15. D. Eliyahu, A. Raz, P. Gruss, D. Givol, and M. Oren Participation of p53 cellular tumour antigen in transformation of normal embryonic cells Nature 312 1984 646 649
16. C.A. Finlay, P.W. Hinds, and A.J. Levine The p53 proto-oncogene can act as a suppressor of transformation Cell 57 1989 1083 1093
17. C. Gaiddon, M. Lokshin, J. Ahn, T. Zhang, and C. Prives A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain Mol. Cell. Biol. 21 2001 1874 1887
18. M. Goggins, G.J. Offerhaus, W. Hilgers, C.A. Griffin, M. Shekher, D. Tang, T.A. Sohn, C.J. Yeo, S.E. Kern, and R.H. Hruban Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+ Am. J. Pathol. 152 1998 1501 1507
19. C.J. Gottardi, E. Wong, and B.M. Gumbiner E-cadherin suppresses cellular transformation by inhibiting beta-catenin signaling in an adhesion-independent manner J. Cell Biol. 153 2001 1049 1060
20. S.A. Hahn, A.B. Seymour, A.T. Hoque, M. Schutte, L.T. da Costa, M.S. Redston, C. Caldas, C.L. Weinstein, A. Fischer, and C.J. Yeo Allelotype of pancreatic adenocarcinoma using xenograft enrichment Cancer Res. 55 1995 4670 4675
21. S.A. Hahn, B. Greenhalf, I. Ellis, M. Sina-Frey, H. Rieder, B. Korte, B. Gerdes, R. Kress, A. Ziegler, and J.A. Raeburn BRCA2 germline mutations in familial pancreatic carcinoma J. Natl. Cancer Inst. 95 2003 214 221
22. D.E. Hansel, S.E. Kern, and R.H. Hruban Molecular pathogenesis of pancreatic cancer Annu. Rev. Genomics Hum. Genet. 4 2003 237 256
23. C.B. Harley, N.W. Kim, K.R. Prowse, S.L. Weinrich, K.S. Hirsch, M.D. West, S. Bacchetti, H.W. Hirte, C.M. Counter, and C.W. Greider Telomerase, cell immortality, and cancer Cold Spring Harb. Symp. Quant. Biol. 59 1994 307 315
24. P. Hinds, C. Finlay, and A.J. Levine Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation J. Virol. 63 1989 739 746
25. S.R. Hingorani, E.F. Petricoin, A. Maitra, V. Rajapakse, C. King, M.A. Jacobetz, S. Ross, T.P. Conrads, T.D. Veenstra, and B.A. Hitt Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse Cancer Cell 4 2003 437 450
26. R.H. Hruban, R.E. Wilentz, and S.E. Kern Genetic progression in the pancreatic ducts Am. J. Pathol. 156 2000 1821 1825
27. R.H. Hruban, N.V. Adsay, J. Albores-Saavedra, C. Compton, E.S. Garrett, S.N. Goodman, S.E. Kern, D.S. Klimstra, G. Kloppel, and D.S. Longnecker Pancreatic intraepithelial neoplasia: A new nomenclature and classification system for pancreatic duct lesions Am. J. Surg. Pathol. 25 2001 579 586
28. R.H. Hruban, C. Iacobuzio-Donahue, R.E. Wilentz, M. Goggins, and S.E. Kern Molecular pathology of pancreatic cancer Cancer J. 7 2001 251 258
29. T. Jacks, L. Remington, B.O. Williams, E.M. Schmitt, S. Halachmi, R.T. Bronson, and R.A. Weinberg Tumor spectrum analysis in p53-mutant mice Curr. Biol. 4 1994 1 7
30. A. Jemal, R.C. Tiwari, T. Murray, A. Ghafoor, A. Samuels, E. Ward, E.J. Feuer, and M.J. Thun Cancer statistics, 2004 CA Cancer J. Clin. 54 2004 8 29
31. D.E. Kardon, L.D. Thompson, R.M. Przygodzki, and C.S. Heffess Adenosquamous carcinoma of the pancreas: A clinicopathologic series of 25 cases Mod. Pathol. 14 2001 443 451
32. M.B. Kastan, O. Onyekwere, D. Sidransky, B. Vogelstein, and R.W. Craig Participation of p53 protein in the cellular response to DNA damage Cancer Res. 51 1991 6304 6311
33. S.E. Kern, K.W. Kinzler, A. Bruskin, D. Jarosz, P. Friedman, C. Prives, and B. Vogelstein Identification of p53 as a sequence-specific DNA-binding protein Science 252 1991 1708 1711
34. P. Kleihues, B. Schauble, A. zur Hausen, J. Esteve, and H. Ohgaki Tumors associated with p53 germline mutations: A synopsis of 91 families Am. J. Pathol. 150 1997 1 13
35. D.S. Klimstra, and D.S. Longnecker K-ras mutations in pancreatic ductal proliferative lesions Am. J. Pathol. 145 1994 1547 1550
36. S.D. Leach Mouse models of pancreatic cancer: The fur is finally flying! Cancer Cell 5 2004 7 11
37. C. Lengauer, K.W. Kinzler, and B. Vogelstein Genetic instability in colorectal cancers Nature 386 1997 623 627
38. C. Lengauer, K.W. Kinzler, and B. Vogelstein Genetic instabilities in human cancers Nature 396 1998 643 649
39. K.D. Lillemoe, C.J. Yeo, and J.L. Cameron Pancreatic cancer: State-of-the-art care CA Cancer J. Clin. 50 2000 241 268
40. E. Montgomery, R.E. Wilentz, P. Argani, C. Fisher, R.H. Hruban, S.E. Kern, and C. Lengauer Analysis of anaphase figures in routine histologic sections distinguishes chromosomally unstable from chromosomally stable malignancies Cancer Biol. Ther. 2 2003 248 252
41. K.M. Murphy, K.A. Brune, C. Griffin, J.E. Sollenberger, G.M. Petersen, R. Bansal, R.H. Hruban, and S.E. Kern Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: Deleterious BRCA2 mutations in 17% Cancer Res. 62 2002 3789 3793
42. K.P. Olive, D.A. Tuveson, Z.C. Ruhe, B. Yin, N.A. Willis, R.T. Bronson, D. Crowley, and T. Jacks Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome Cell 119 2004 847 860
43. M. Olivier, R. Eeles, M. Hollstein, M.A. Khan, C.C. Harris, and P. Hainaut The IARC TP53 database: New online mutation analysis and recommendations to users Hum. Mutat. 19 2002 607 614
44. M. Olivier, D.E. Goldgar, N. Sodha, H. Ohgaki, P. Kleihues, P. Hainaut, and R.A. Eeles Li-Fraumeni and related syndromes: Correlation between tumor type, family structure, and TP53 genotype Cancer Res. 63 2003 6643 6650
45. L.F. Parada, H. Land, R.A. Weinberg, D. Wolf, and V. Rotter Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation Nature 312 1984 649 651
46. C. Prives Signaling to p53: Breaking the MDM2-p53 circuit Cell 95 1998 5 8
47. A. Rangarajan, and R.A. Weinberg Opinion: Comparative biology of mouse versus human cells: Modelling human cancer in mice Nat. Rev. Cancer 3 2003 952 959
48. E. Rozenblum, M. Schutte, M. Goggins, S.A. Hahn, S. Panzer, M. Zahurak, S.N. Goodman, T.A. Sohn, R.H. Hruban, C.J. Yeo, and S.E. Kern Tumor-suppressive pathways in pancreatic carcinoma Cancer Res. 57 1997 1731 1734
49. A. Scarpa, P. Capelli, K. Mukai, G. Zamboni, T. Oda, C. Iacono, and S. Hirohashi Pancreatic adenocarcinomas frequently show p53 gene mutations Am. J. Pathol. 142 1993 1534 1543
50. F.S. Schreiber, T.B. Deramaudt, T.B. Brunner, M.I. Boretti, K.J. Gooch, D.A. Stoffers, E.J. Bernhard, and A.K. Rustgi Successful growth and characterization of mouse pancreatic ductal cells: Functional properties of the Ki-RAS(G12V) oncogene Gastroenterology 127 2004 250 260
51. M. Schutte, R.H. Hruban, J. Geradts, R. Maynard, W. Hilgers, S.K. Rabindran, C.A. Moskaluk, S.A. Hahn, I. Schwarte-Waldhoff, and W. Schmiegel Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas Cancer Res. 57 1997 3126 3130
52. O.M. Sieber, K. Heinimann, and I.P. Tomlinson Genomic instability-the engine of tumorigenesis? Nat. Rev. Cancer 3 2003 701 708
53. A. Smogorzewska, J. Karlseder, H. Holtgreve-Grez, A. Jauch, and T. de Lange DNA ligase IV-dependent NHEJ of deprotected mammalian telomeres in G1 and G2 Curr. Biol. 12 2002 1635 1644
54. P. Tarapore, and K. Fukasawa Loss of p53 and centrosome hyperamplification Oncogene 21 2002 6234 6240
55. S.P. Thayer, M.P. di Magliano, P.W. Heiser, C.M. Nielsen, D.J. Roberts, G.Y. Lauwers, Y.P. Qi, S. Gysin, C. Fernandez-del Castillo, and V. Yajnik Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis Nature 425 2003 851 856
56. A.L. Warshaw, and C. Fernandez-del Castillo Pancreatic carcinoma N. Engl. J. Med. 326 1992 455 465
57. H. Yamamoto, F. Itoh, H. Nakamura, H. Fukushima, S. Sasaki, M. Perucho, and K. Imai Genetic and clinical features of human pancreatic ductal adenocarcinomas with widespread microsatellite instability Cancer Res. 61 2001 3139 3144
58. C.J. Yeo, J.L. Cameron, K.D. Lillemoe, T.A. Sohn, K.A. Campbell, P.K. Sauter, J. Coleman, R.A. Abrams, and R.H. Hruban Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: Randomized controlled trial evaluating survival, morbidity, and mortality Ann. Surg. 236 2002 355 366
59. T.P. Yeo, R.H. Hruban, S.D. Leach, R.E. Wilentz, T.A. Sohn, S.E. Kern, C.A. Iacobuzio-Donahue, A. Maitra, M. Goggins, and M.I. Canto Pancreatic cancer Curr. Probl. Cancer 26 2002 176 275